Monoclonal Antibody Based Products

Published by: Global Industry Analysts

Published: Aug. 1, 2006 - 487 Pages

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

Therapeutics

Cancer

Other Therapeutic Mabs

Diagnostics

Cancer

Other Diagnostic MAbs

II. EXECUTIVE SUMMERY

1. Industry Overview

World MAb-Based Products Market: A Profile

Genomics Research Leads Way to New Monoclonal Antibodies

Bright Outlook for MAbs

Current and Future Analysis

Regional Perspective

Product Segment Perspective

Competitive Scenario

Table 1: Monoclonal Antibody Based Products Market (2004): Percentage Breakdown of Leading Manufacturers by Sales for Genentech, Johnson & Johnson, Roche, Abbott, MedImmune, Schering Plough, Eli Lilly, and Others (includes corresponding Graph/Chart)

Table 2: Monoclonal Antibody Based Products Market (2004): Percentage Breakdown of Leading Drugs by Sales for Remicade, Rituxan, Herceptin, Synagis, Humira, Avastin, ReoPro, Erbitux, Xolair, and Others (includes corresponding Graph/Chart)

Therapeutic Antibodies in the Market: 2004

Drug Developers Trying to Break the Shackles

Rituximab Vs. Epratuzumab

A Revolution Not too Far

Milestones in Development of MAbs

Focus on Unmet Medical Needs in the Emerging Markets

2. Industry Analysis

Trends and Issues

Shift Towards Humanized and Fully Human Antibodies

Ageing Baby Boomers Spur MAbs Growth

Booming Period for Therapeutic Antibodies

Partnerships and Collaborations Spark Increase in Profit Margins

High Costs Impede MAbs Penetration

Opportunities in Technology Development

Worldwide Select Antibody Technology Companies

Increasing Demand for Protein A in MAb Manufacturing

Economic and Humane Concerns Limit Antibody Production in Mice

FCA- A Major Cause for Discomfort in Mice

Widespread Utilization of MAb Technology in Pharmaceuticals Market

3. Product Overview

Immune System: Natural Defenders

Human Antibodies

Antibodies Offer Natural Immunity

Induction of The Immune Process

Mechanism of Action

Polyclonal and Monoclonal Antibodies

Production of Monoclonal Antibodies

Traditional Methods

The Hybridoma Technology

Separation and Purification of Monoclonals

Factors Impacting Production of MAbs

Types of Monoclonal Antibodies

Table 3: Monoclonal Antibody Market by Product Type (2004 & 2010): Percentage Breakdown by Sales for Chimeric, Humanized, Fully Human, Fragment, and Conjugated (includes corresponding Graph/Chart)

Murine Monoclonal Antibodies

Humanized Antibodies/CDR Grafted Antibodies

Murine Vs Human Monoclonal Antibodies

Chimeric Antibodies: Show Lesser Antigenicity

Fully Human Antibodies

Bispecific Antibodies

Certain Limitations Do Exist

Advantages of MAbs

Advantages and Limitations of MAb Technologies

4. Diagnostic Applications of Monoclonal Antibodies

Monoclonal Antibody Based Diagnostics

Immunodiagnostics

Monoclonals Used as Targeting Agents

Radio labeled Monoclonal Antibodies for Diagnostic Imaging

The Pros and Cons of MAb-Based Immunoconjugates

Cytogen: The First to Introduce A Monoclonal Antibody- based Cancer Agent

NeoProbe’s Radioimmunogzuided Surgery

Mechanism of Working

Cancer

A Historical Overview

Initial Hiccups

Tumor Markers

Pregnancy/Fertility Testing

5. Monoclonal Antibody-Based Therapeutics For Cancer

Evolution of Therapeutic Antibody Products

Advantages of Therapeutic Monoclonal Antibodies

Current Scenario in Monoclonal Antibody Therapeutics Market

Table 4: Monoclonal Antibody Market by Therapy Area (2004 & 2010): Percentage Breakdown by Sales for Oncology, Arthritis, Immune & Inflammatory Disorders, Infectious Diseases, Cardiovascular, Respiratory, Ophthalmology, and CNS (includes corresponding Graph/Chart)

Cancer Therapeutics

Monoclonal Antibodies Offer Hope Against Cancer

Antibody Therapies for Cancer

Cancer: A Serious Issue and Plaguing Illness Worldwide

Status of MAbs for Cancer in 2004

Breast Cancer: The Most Common Form of Cancer in American Women

Breast Cancer - Treatment Options

Monoclonal Antibodies Against NHL

Monoclonal Antibodies Against Ovarian Cancer

MAb Immunotherapy - Effective for Residual Ovarian Cancer

Melanoma

MAbs Linked With Toxins Found Effective

Immunologic Effector Functions

Colorectal Cancer: Rising Incidence

Panorex: The First Cancer Therapeutic in the Market

Myeloid Leukemia

Prostrate Cancer

Cancers of the Immune System

Non-Hodgkin’s Lymphoma

Monoclonal Antibodies Attack Residual Cancer

What the Future Holds

6. Other Therapeutic Monoclonal Antibodies

Therapeutic Monoclonal Antibody Drugs and Applications

MAbs used in Clinical Field

Inflammation Therapeutics

Inflammation

Asthma: A Chronic Affliction

CGP 51 901 To Treat Asthma

Autoimmune Diseases

What Goes Wrong

Intervention Better Than Prevention

Some Autoimmune Diseases

Multiple Sclerosis

Crohn’s Disease

Rheumatoid Arthritis

Organ Transplantation

Biology of Transplantation

Types of Transplants

Autografts

Syngeneic Transplants

Allografts

Xenografts

Follow-up Treatment

Products to Counter Rejection

OKT3: A Monoclonal Already in the Market

Infectious Diseases

Sepsis

A Rapid Process

Gram Negative Bacteria are the Causative Agents

A Retrospect

Monoclonal Antibodies and Septic Shock

What is HIV/AIDS

What is AIDS?

Global Statistics

HIV/AIDS Testing

Monoclonal Antibodies and HIV

Cardiovascular

Cardiovascular Diseases are Fatal

Treatment Options

Causes of Cardiovascular Diseases

ReoPro: The Solution to the Problem

7. Regulation Impacting The Industry

Regulations in the U.S

Approval: A Laborious Process

Clinical Trials

Orphan Drug Status

8. Contract Manufacturing

Outlook

9. Research and Development Activities

Rituxan and Herceptin from Genentech

FuCell hybridomas

Test-tube MAbs/Phase Display Library

Rituxan for Cancer Treatment

GenMAb Develops Fully Human Antibodies

Protein Design Labs Licenses Trioma

Protein Design Labs’ Innovative Technology

10. Product Launches and Developments

Biotest AG and AERES Biomedical Develop BT-062

Genentech Launches Avastin

Biotest Unveils Intratect®

Genentech Introduces Xolair

Genentech Unveils Raptiva

Corixa Presents BEXXAR

IGEN Launches Monoclonal Antibody Therapies

MAb Against Pseudomonas Aeruginosa

Wyeth Introduces Mylotarg

Generics Launches Herceptin

11. Recent Industry Activity

Merck to Acquire Abmaxis

Micromet to Merge with CancerVax

PharmAthene to Merge Operations with SIGA

FDA Clears IND for CYT-500 Monoclonal Antibody from Cytogen

LSP Acquires Global License for Monoclonal Antibodies fromLudwig Institute

Seattle Genetics in Agreement with Laureate to Manufacture Monoclonal Antibody Drug Candidates

EU Grants Orphan Drug Designation to GPC’s Anticancer Monoclonal Antibody

Laureate Collaborates with Bradmer on Neuradiab Monoclonal Antibody for Cancer Treatment

Amgen Takes Over Abgenix

Celera and Medarex in Strategic Alliance for Developing Human Monoclonal Antibody Therapeutics

UCB Collaborates with Immunomedics

Crucell Collaborates with DSM for Monoclonal Antibody Licensing Business

Roche Licenses Rabbit Monoclonal Antibody Technology from Epitomics

BioGenex Receives FDA Pre-Market Approval for InSite™ Monoclonal Antibody

Upstate Bags Marketing Rights for Anti-ZAP-70 Monoclonal Antibody

XOMA Bags NIAID Contract to Develop Anti-Botulinum Neurotoxin Monoclonal Antibodies

HGS Bags Two-Phase Contract for ABthrax™ MAb from the US Government

Medarex and PharmAthene Receive Funding for Development of Valortim™

UCB Collaborates with Millenium

MorphoSys Acquires Two Antibody Technology Companies

Tanabe Seiyaku and Remicade Sign Addendum

Abgenix Receives Royalty from Human Genome

Amgen Acquires Tularik

Sunesis Pharmaceuticals Collaborates with Biogen Idec

H3 Pharma Inc. Enters into a Manufacturing Agreement with DSM Biologics

EMBL and Abnova Inks Collaboration Agreement

AstraZeneca and CAT in Five-Year Strategic Alliance for Monoclonal Antibody Research

UCB Acquires Celltech

ImmunoGen Signs Licensing Agreement with Biogen

Lonza Inks MAbs Manufacturing and Supply Agreement with NovImmune

Avanir and Peregrine Sign License Agreement

BioVest Concludes Agreement with Bioventix

Roche to Set Up Two Manufacturing Facilities in Switzerland

XTL Biopharm Bags European patent for Human Monoclonal Anti Body

MBL and Medarex Bags FDA approval for CDA-1 Phase I Trials

Health Canada Approves HUMIRA

CAT Signs Licensing Agreement with Micromet

CAT Enters into Agreement with Genzyme

Medarex and Avlon Enter into Agreement

Micromet, Enzon and CAT Sign Cross-License Agreement

Xerion and CAT Enter into Agreement

Genetastix and Nissho Enter into Agreement

InNexus and Corixa Enter into Agreement

Abbott Collaborates with LigoCyte

CAT Acquires Drug Royalty Corporation

CAT and Amrad Join Hands for Research

IDEC's Receives FDA Approval for Zevalin

Medarex Enters into Research Alliance with Seattle Genetics

Dow, Epicyte and Centocor Join Forces to Develop Monoclonal Antibody

Eos, Medarex and Biosite in Alliance for Cancer Treatment

Imgenex forms Alliance with GMO

CAT and Elan Enter into Strategic Alliance

Bioinvent International Enters into Agreement with Novo Nordisk for Drug Discovery Research

Epicyte and Dow Chemical Enter into Agreement

Rockland Announces the Completion of Laboratory Expansion

Roche’s MAbThera Receives Approval in Japan

Aviva Launches Manufacturing and Marketing Operations

ICOS and Seattle Enters into Joint Development and Manufacturing Agreement

Medarex and Corixa Team-up to Develop Human Monoclonal Antibodies

Taisho Enters into Research Alliance with IDEC

PDL Signs Agreement with InterMune

ProMetic Signs Agreement with Integrated Protein

Medarex Signs Agreement with ZynloGenetics

CAT Joins Hands with GD. Searle

Medarex and MedImmune Enter into Antibody Research Agreement

Lonza Signs Agreement with ImClone Systems

MedImmune and Alkermes Enter into Agreement

GTC and Abgenix Enter into Production Agreement

Genzyme Transgenics Expands Agreement with Centocor

PDL and InterMune Enter into an Agreement

12. Focus on Select Global Players

Amgen (US)

BD Biosciences (US)

Biogen Idec Inc (US)

Biotest AG (Germany)

Cambridge Antibody Technology (UK)

Dendreon Corporation (US)

Elan Corporations Plc (Ireland)

Eli Lilly (US)

Genentech, Inc. (USA)

Guildhay (UK)

Human Genome Sciences (US)

ICOS (US)

Immunomedics (US)

Johnson & Johnson (US)

Centocor (US)

Medarex, Inc. (US)

MedImmune, Inc. (US)

PDL BioPharma (US)

Schering-Plough Corporation (US)

Strategic BioSolutions (US)

UCB Group (Belgium)

Wyeth Pharmaceuticals (US)

13. Global Market Perspective

Table 5: World Recent Past, Current & Future Market Analysis for Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 6: World 10-Year Perspective for Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart)

Table 7: World Recent Past, Current & Future Market Analysis for Therapeutic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 8: World Recent Past, Current & Future Market Analysis for Therapeutic Monoclonal Antibody Based Products by Segment - Cancer and Other Therapeutics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 9: World 10-Year Perspective for Therapeutic Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe Asia- Pacific, and Rest of World Markets for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart)

Table 10: World 10-Year Perspective for Therapeutic Monoclonal Antibody Based Products by Segments - Percentage Breakdown of Dollar Sales for Cancer and Other Therapeutics Markets for Years 2000, 2005 & 2010

Table 11: World Recent Past, Current & Future Market Analysis for Cancer Therapeutic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 12: World 10-Year Perspective for Cancer Therapeutic Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe Asia-Pacific, and Rest of World Markets for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart)

Table 13: World Recent Past, Current & Future Market Analysis for Other Therapeutic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 14: World 10-Year Perspective for Other Therapeutic Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe Asia-Pacific, and Rest of World Markets for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart)

Table 15: World Recent Past, Current & Future Market Analysis for Diagnostic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 16: World Recent Past, Current & Future Market Analysis for Diagnostic Monoclonal Antibody Based Products by Segments - Cancer and Other Diagnostics Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 17: World 10-Year Perspective for Diagnostic Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe Asia -Pacific, and Rest of World Markets for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart)

Table 18: World 10-Year Perspective for Diagnostic Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Cancer and Other Diagnostics Markets for Years 2000, 2005 & 2010

Table 19: World Recent Past, Current & Future Market Analysis for Cancer Diagnostic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 20: World 10-Year Perspective for Cancer Diagnostic Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe Asia-Pacific, and Rest of World Markets for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart)

Table 21: World Recent Past, Current & Future Market Analysis for Other Diagnostic Monoclonal Antibody Based Products by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 22: World 10-Year Perspective for Other Diagnostic Monoclonal Antibody Based Products by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe Asia-Pacific, and Rest of World Markets for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart)

III. MARKET

1. The Untied States

A.Market Analysis

Global Hub of MAbs

Approved Therapeutic Antibodies in the US as of 2004

New Heights f or US Cancer Therapeutics

Focus on Key Players

Abgenix

BD Biosciences

Biogen Idec.

Dendreon Corporation

Eli Lilly

Genentech, Inc.

Human Genome Sciences

ICOS

Immunomedics

Johnson & Johnson

Centocor

Medarex, Inc.

MedImmune, Inc

PDL BioPharma

Schering-Plough Corporation

Strategic BioSolutions

Wyeth Pharmaceuticals

Product launches

Strategic Developments

Historic Developments

B.Market Analytics

Table 23: US Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics (Cancer and Others) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 24: US 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others), and Diagnostics (Cancer and Others) Markets for 2000, 2005 & 2010

2. Canada

A.Market Analysis

Strategic Developments

B.Market Analytics

Table 25: Canadian Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics (Cancer and Others) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 26: Canadian 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics (Cancer and Others) Markets for 2000, 2005 & 2010

3. Japan

A.Market Analysis

Strategic Developments

B.Market Analytics

Table 27: Japanese Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics (Cancer and Others) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010, (includes corresponding Graph/Chart)

Table 28: Japanese 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics (Cancer and Others) Markets for 2000, 2005 & 2010

4. Europe

A.Market Analysis

Biotechnology and Pharmacy Research

Monoclonal Antibody Based Products Market in Europe

Trends in Select European Countries

Approved Therapeutic Antibodies in Europe as of 2004

Historic Development

B.Market Analytics

Table 29: European Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Geographic Region - France, Germany, Italy, UK & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 30: European Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment - Therapeutics (Cancer and Others), and Diagnostics (Cancer and Others) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 31: European 10-Year Perspective for Monoclonal Antibody Based Products by Geographic Region -Percentage Breakdown of Dollar Sales for France, Germany, Italy, the UK, and Rest of Europe for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart)

Table 32: European 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics (Cancer and Others) Markets for 2000, 2005 & 2010

4a. France

Market Analysis

Table 33: French Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment -Therapeutics (Cancer and Others), and Diagnostics (Cancer and Others) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 34: French 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others), and Diagnostics (Cancer and Others) Markets for 2000, 2005 & 2010

4b. Germany

A.Market Analysis

Biotest AG- A Key Player

Product Launches

Strategic Developments

B.Market Analytics

Table 35: German Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment -Therapeutics (Cancer and Others), and Diagnostics (Cancer and Others) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 36: German 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics (Cancer and Others) Markets for 2000, 2005 & 2010

4c. Italy

Market Analysis

Table 37: Italian Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment -Therapeutics (Cancer and Others), and Diagnostics (Cancer and Others) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 38: Italian 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics (Cancer and Others) Markets for 2000, 2005 & 2010

4d. The United Kingdom

A.Market Analysis

Focus on Key Players

Cambridge Antibody Technology (CAT)

Guildhay

Strategic Developments

B.Market Analytics

Table 39: UK Recent Past, Current & Future Analysis for Monoclonal Antibody Based Products by Segment -Therapeutics (Cancer and Others), and Diagnostics (Cancer and Others) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 40: UK 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others), and Diagnostics (Cancer and Others) Markets for 2000, 2005 & 2010

4e. Rest of Europe

A.Market Analysis

Key Players

Elan Corporations Plc (Ireland)

UCB Group (Belgium)

Strategic Developments

B.Market Analytics

Table 41: Rest of Europe Market for Monoclonal Antibody Based Products - Recent Past, Current & Future Analysis by Product Segment for Therapeutics (Cancer and Others), and Diagnostics (Cancer and Others) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 42: Rest of Europe 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics (Cancer and Others) Markets for 2000, 2005 & 2010

5. Asia-Pacific

A.Market Analysis

Indian Market

Strategic Developments

B.Market Analytics

Table 43: Asia-Pacific Market for Monoclonal Antibody Based Products - Recent Past, Current & Future Analysis by Product Segment for Therapeutics (Cancer and Others), and Diagnostics (Cancer and Others) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 44: Asia-Pacific 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others), and Diagnostics (Cancer and Others) Markets for 2000, 2005 & 2010

6. Rest of World

Market Analysis

Table 45: Rest of World Market for Monoclonal Antibody Based Products - Recent Past, Current & Future Analysis by Product Segment for Therapeutics (Cancer and Others), and Diagnostics (Cancer and Others) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 46: Rest of World 10-Year Perspective for Monoclonal Antibody Based Products by Segment - Percentage Breakdown of Dollar Sales for Therapeutics (Cancer and Others),and Diagnostics (Cancer and Others) Markets for 2000, 2005 & 2010

IV. COMPETITION

1. Abbott Laboratories (USA)

Table 47: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ billion)

Table 48: Annual Sales Analysis: 2004-2005 (In US$ billion)

2. Abnova Corporation (Taiwan)

3. American Diagnostica, Inc. (USA)

4. American Qualex (USA)

5. Amgen, Inc. (USA)

Table 49: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)

Table 50: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 51: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

6. Antibodies, Inc. (USA)

7. Avanir Pharmaceuticals (USA)

Table 52: Nine Months Sales Analysis: 2005-2006 (Nine Months ended, June) (In US$ million)

Table 53: Nine Months Sales Analysis by Quarter: 2005- 2006 (Nine Months ended, June) (In US$ million)

Table 54: Nine Months Sales Analysis by Business Segment: 2005-2006 (Nine Months ended, June) (In US$ million)

Table 55: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 56: Quarterly Sales Analysis: 2004-2005 (In US$ million)

Table 57: Annual Sales Analysis by Business Segment: 2004-2005 (In US$ million)

8. Beckman Coulter, Inc. (USA)

Table 58: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)

Table 59: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 60: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)

Table 61: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

9. Becton Dickinson and Company (USA)

Table 62: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)

Table 63: Half Yearly Sales Analysis by Quarter: 2005- 2006 (H1) (In US$ million)

Table 64: Half Yearly Sales Analysis by Segment: 2005- 2006 (H1) (In US$ million)

Table 65: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 66: Quarterly Sales Analysis: 2004-2005 (In US$ million)

Table 67: Annual Sales Analysis by Business Segment: 2004-2005 (In US$ million)

Table 68: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

BD Biosciences (USA)

10. Binding Site Ltd. The (UK)

11. Bioclone Australia Pty., Ltd. (Australia)

12. Biogen Idec, Inc. (USA)

Table 69: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ billion)

Table 70: Annual Sales Analysis: 2004-2005 (In US$ billion)

Table 71: Quarterly Sales Analysis: 2004-2005 (In US$ billion)

13. Biogenex Laboratories, Inc. (USA)

14. BioInvent International AB (Sweden)

15. Biomérieux SA (France)

Table 72: Annual Sales Analysis: 2004-2005 (In € million)

Biomerieux, Inc. (USA)

16. Biomira, Inc. (Canada)

Biomira USA, Inc. (USA)

17. Biosource International, Inc. (USA)

18. Biotest AG (Germany)

19. Bioventix (UK)

20. Bradmer Pharmaceuticals, Inc. (Canada)

21. Calbiochem (USA)

22. Cambrex Corporation (USA)

Table 73: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)

Table 74: Quarterly Sales Analysis: 2005-2006 (H1) (In US$ million)

Table 75: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 76: Quarterly Sales Analysis: 2004-2005 (In US$ million)

23. Cambridge Antibody Technology (UK)

Table 77: Half Yearly Sales Analysis: 2004-2005 (H1) (In £ million)

24. Capricorn Products, Inc. (USA)

25. Celera Genomics Group (USA)

26. Celgene Corporation (USA)

Table 78: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)

Table 79: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 80: Quarterly Sales Analysis: 2004-2005 (In US$ million)

Table 81: Annual Sales Analysis by Business Segment: 2004-2005 (In US$ million)

Table 82: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

27. Chemicon International, Inc. (USA)

28. Crucell NV (The Netherlands)

Table 83: First Quarter Sales Analysis: 2005-2006 (Q1) (In million)

Table 84: Annual Sales Analysis: 2004-2005 (In € million)

Table 85: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million)

Berna Biotech AG (Switzerland)

29. Cytogen Corporation (USA)

Table 86: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)

Table 87: Half Yearly Sales Analysis by Business Operations: 2005-2006 (H1) (In US$ million)

Table 88: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 89: Quarterly Sales Analysis: 2004-2005 (In US$ million)

Table 90: Annual Sales Analysis by Business Operations: 2004-2005 (In US$ million)

30. Dakocytomation Denmark A/S (Denmark)

Dakocytomation (USA)

Dakocytomation Diagnosticos SA (Spain)

31. Dendreon Corporation (USA)

Table 91: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)

Table 92: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 93: Quarterly Sales Analysis: 2004-2005 (In US$ million)

32. DiaSorin SpA (Italy)

Diasorin, Inc. (USA)

33. DRG International, Inc. (USA)

DRG Instruments GmbH (Germany)

DRG Medtek SP Z o o (Poland)

34. DSM Biologics (The Netherlands)

35. ELAN Corporation PLC (Ireland)

Table 94: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)

Table 95: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 96: Annual Sales Analysis By Segment: 2004-2005 (In US$ million)

Table 97: Annual Sales Analysis By Geographic Region: 2004-2005 (In US$ million)

36. Eli Lilly and Company (USA)

Table 98: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ billion)

Table 99: First Quarter Sales Analysis by Business Segment: 2005-2006 (Q1) (In US$ billion)

Table 100: First Quarter Sales Analysis by Product Segment: 2005-2006 (Q1) (In US$ billion)

Table 101: Annual Sales Analysis: 2004-2005 (In US$ billion)

Table 102: Quarterly Sales Analysis: 2004-2005 (In US$ billion)

Table 103: Annual Sales Analysis by Business Segment: 2004-2005 (In US$ billion)

Table 104: Annual Sales Analysis by Product Segment: 2004-2005 (In US$ billion)

Table 105: Annual Sales Analysis by Geographical Region: 2004-2005 (In US$ billion)

37. EMD Biosciences, Inc. (USA)

38. Endogen, Inc. (USA)

39. Enzo Diagnostics, Inc. (USA)

40. Epitomics, Inc. (USA)

41. Exocell, Inc. (USA)

42. Fujirebio Diagnostics, Inc. (USA)

43. Genentech, Inc. (USA)

Table 106: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)

Table 107: First Quarter Sales Analysis by Product: 2005-2006 (Q1) (In US$ million)

Table 108: Annual Sales Analysis: 2003-2005 (In US$ million)

Table 109: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

Table 110: Annual Sales Analysis by Product: 2004-2005 (In US$ million)

44. Genzyme Corporation (USA)

Table 111: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ billion)

Table 112: Annual Sales Analysis: 2004-2005 (In US$ billion)

Table 113: Quarterly Sales Analysis: 2004-2005 (In US$ billion)

Table 114: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion)

Table 115: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion)

Genzyme Diagnostics (USA)

Genzyme Virotech GmbH (Germany)

45. GlaxoSmithKline PLC (UK)

Table 116: Annual Sales Analysis: 2003-2005 (In £ million)

Table 117: Annual Sales Analysis by Segment: 2004-2005 (In £ million)

Table 118: Annual Sales Analysis by Segment: 2003-2004 (In £ million)

46. Goodwin Biotechnology, Inc. (USA)

47. GPC Biotech AG (Germany)

Table 119: First Quarter Sales Analysis: 2005-2006 (Q1) (In € million)

Table 120: Annual Sales Analysis: 2004-2005 (In € million)

48. Guildhay Ltd. (UK)

49. Debiovision Inc

50. Human Genome Sciences, Inc. (USA)

Table 121: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)

Table 122: Annual Sales Analysis: 2003-2005 (In US$ million)

51. ICOS Corporation (USA)

Table 123: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ thousands)

Table 124: Annual Sales Analysis: 2003-2004 (In US$ thousands)

Table 125: Annual Sales Analysis by Quarter: 2003-2004 (In US$ thousands)

52. Igen International, Inc. (USA)

53. Immunodiagnostics, Inc. (USA)

54. ImmunoGen, Inc. (USA)

Table 126: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)

Table 127: Annual Sales Analysis: 2003-2005 (In US$ million)

Table 128: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

Table 129: Annual sales Analysis by Segment: 2004-2005 (In US$ million)

55. Immunomedics, Inc. (USA)

Table 130: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, March) (In US$ million)

Table 131: Nine Months Ended Sales Analysis: 2005-2006 (Nine Months Ended, March) (In US$ thousands)

Table 132: Annual Sales Analysis: 2004-2005 (In US$ thousands)

Table 133: Annual Sales Analysis by Geographical Region: 2004-2005 (In US$ thousands)

56. Immunovision, Inc. (USA)

57. Intersciences, Inc. (Canada)

58. Johnson & Johnson (USA)

Table 134: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ billion)

Table 135: First Quarter Sales Analysis by Segment: 2005-2006 (Q1) (In US$ billion)

Table 136: First Quarter Sales Analysis by Geographic Region: 2005-2006 (Q1) (In US$ billion)

Centocor Inc. (USA)

Ortho-Clinical Diagnostics (USA)

Ortho-Clinical Diagnostics (UK)

59. Korea Research Institute Of Bioscience and Biotechnology (Korea)

60. Labfrontier Co., Ltd. (Korea)

61. Lampire Biological Laboratories (USA)

62. Laureate Pharma Inc. (USA)

63. Life Science Pharmaceuticals, Inc. (USA)

64. Lonza Group Ltd. (Switzerland)

65. Medarex, Inc. (USA)

Table 137: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)

Table 138: Annual Sales Analysis: 2003-2005 (In US$ million)

Table 139: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

66. Mediagnost GmbH (Germany)

67. Medicorp, Inc. (Canada)

68. MedImmune, Inc. (USA)

Table 140: First Quarter sales Analysis: 2005-2006 (In US$ million)

Table 141: First Quarter Sales Analysis by Business Operations: 2006-2005 (In US$ million)

Table 142: Annual Sales Analysis: 2003-2005 (In US$ million)

Table 143: Annual sales Analysis by Business Operations: 2004-2005 (In US$ million)

Table 144: Annual sales Analysis by Geographic Region: 2004-2005 (In US$ million)

69. Micromet, Inc. (USA)

Table 145: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)

Table 146: Quarterly Sales Analysis: 2005-2006 (H1) (In US$ million)

Table 147: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 148: Quarterly Sales Analysis: 2004-2005 (In US$ million)

70. Morphosys AG (Germany)

71. New Horizons Diagnostic Corporation (USA)

72. Olympus America, Inc. (USA)

73. One Lambda Inc. (USA)

74. Oxoid, Inc. (USA)

75. PDL Biopharma, Inc. (USA)

Table 149: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)

Table 150: Annual Sales Analysis: 2003-2005 (In US$ million)

Table 151: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

Table 152: Annual Sales Analysis by Quarter: 2003-2004 (In US$ million)

76. Peptech Technology Ltd. (Australia)

Table 153: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)

Table 154: Half Yearly Sales Analysis By Business Segments: 2005-2006 (H1) (In US$ million)

Table 155: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 156: Annual Sales Analysis By Business Segments: 2004-2005 (In US$ million)

77. Peregrine Pharmaceuticals, Inc. (USA)

Table 157: Annual Sales Analysis: 2004-2006 (In US$ million)

Table 158: Annual Sales Analysis by Segment: 2005-2006 (In US$ million)

Table 159: Annual Sales Analysis by Quarter: 2005-2006 (In US$ million)

Table 160: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)

78. Pharmathene, Inc. (USA)

79. Protein Design Labs, Inc. (USA)

Table 161: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)

Table 162: Half Yearly Sales Analysis by Quarter: 2005 -2006 (H1) (In US$ million)

Table 163: Annual Sales Analysis: 2003-2005 (In US$ million)

80. Roche Diagnostics (Schweiz) AG (Switzerland)

81. Schering-Plough Corporation (USA)

Table 164: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 165: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)

Table 166: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

Table 167: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

82. Scimedx Corporation (USA)

83. Seattle Genetics, Inc. (USA)

Table 168: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)

Table 169: Half Yearly Sales Analysis by Quarter: 2005 -2006 (H1) (In US$ million)

Table 170: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 171: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

84. Sifin Institut Für Immunpräparate Und Nährmedien GmbH (Germany)

85. Siga Technologies, Inc. (USA)

Table 172: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)

Table 173: Annual Sales Analysis: 2004-2005 (In US$ thousands)

Table 174: Annual Sales Analysis by Qurater: 2004-2005 (In US$ million)

86. Signet Laboratories, Inc. (USA)

87. Spectral Diagnostics, Inc. (Canada)

Table 175: First Quarter Sales Analysis: 2006-2007 (Q1) (In Can$ million)

Table 176: Annual Sales Analysis: 2005-2006 (In US$ million)

Table 177: Annual Sales Analysis by Quarter: 2005-2006 (In Can$ million)

Table 178: Annual Sales Analysis by Geographic Region: 2005-2006 (In Can$ million)

88. STI-Signal Transduction Products (USA)

89. Strategic BioSolutions (USA)

90. Sunesis Pharmaceuticals, Inc. (USA)

Table 179: Half Yearly Analysis: 2005-2006 (H1) (In US$ million)

Table 180: Half Yearly Analysis by Quarter: 2005-2006 (H1) (In US$ million)

Table 181: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 182: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

91. Tanabe Seiyaku Co., Ltd. (Japan)

Table 183: First Quarter Sales Analysis: 2006-2007 (Q1) (In US$ million)

Table 184: First Quarter Sales Analysis by Business Segment: 2005-2006 (Q1) (In Yen million)

Table 185: Annual Sales Analysis: 2005-2006 (In US$ million)

Table 186: Annual Sales Analysis by Business Segment: 2004-2005 (In Yen million)

92. Tanox, Inc. (USA)

Table 187: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)

Table 188: Half Yearly Sales Analysis by Quarter: 2005 -2006 (H1) (In US$ million)

Table 189: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

Table 190: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ thousand)

93. Trinity Biotech PLC (Ireland)

Table 191: Annual Sales Analysis: 2004-2005 (In US$ million)

Table 192: Annual Sales Analysis by Product Segment: 2004-2005 (In US$ million)

Table 193: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

94. UCB SA (Belgium)

Table 194: Annual Sales Analysis: 2004-2005 (In € million)

Table 195: Annual Sales Analysis by Product: 2004-2005 (In € million)

Table 196: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million)

95. Upstate Group LLC (USA)

96. Virostat, Inc. (USA)

97. Virexx Medical Corporation (Canada)

Table 197: Annual Sales Analysis: 2003-2004 (In Can$ million)

Altarex Medical Corporation (Canada)

98. Wyeth (USA)

Table 198: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)

Table 199: First Quarter Sales Analysis by Segment: 2005-2006 (Q1) (In US$ million)

Table 200: Annual Sales Analysis: 2003-2005 (In US$ million)

99. Xoma Ltd. (USA)

Abstract

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location. Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Titles available via "online download" are not affected by this and are still delivered to your personal library immediately.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.